Investor Presentation

July 2011

For

per

sona

l use

onl

y

DISCLAIMER

� This presentation is not and does not form part of any offer, invitation or recommendation in respect of securities. Any decision to buy or sell NuSep securities or other products should be made only after seeking appropriate financial advice. Reliance should not be placed on information or opinions contained in this presentation and subject only to any legal obligation to do so, the Company does not accept any obligation to correct or update them. This presentation does not take into consideration the investment objectives, financial situation or particular needs of any particular investor.

� To the fullest extent permitted by law, NuSep and its affiliates and their respective officers, directors, employees and agents, accept no responsibility for any information provided in this presentation, including any forward looking information, and disclaim and liability whatsoever (including for negligence) for any loss howsoever arising from any use of this presentation or reliance on anything contained in or omitted from it or otherwise arising in connection with this.

For

per

sona

l use

onl

y

NuSep’s Global Structure

Singapore - NuSep Asia

Sydney – NuSep Holdings Ltd.

Atlanta – NuSep, Inc.

Germany – NuSep Europe

For

per

sona

l use

onl

y

Corporate Structure

• Consumables Division

� Gels

� IQ Software

• Clinical Division

� IVF SpermSep

• Therapeutic Division

� PrIME Therapeutic Plasma Mini Mill

For

per

sona

l use

onl

y

Board & Management

BOARD

• John Manusu – Executive Chairman

• Dr Hari Nair – Managing Director

• Bill Spee – Non Executive Director

• Iain Sorrell – Non Executive Director

MANAGEMENT

• Prakash Patel – COO & Company Secretary

• Dr James Atwood – GM US

• Dr John Andrews - CSOFor

per

sona

l use

onl

y

NuSep’s Technology Roadmap

NuSep’s Vision - To be the Premier Technology Supplier in the BioSeparations Market

PrIME Fractionation

High

Low

Technology Shift

Market Potential

SpermSep

ProteoIQ

nUViewConsumables Division$200m Market

Clinical Division$110m Market

Therapeutic Division$10B Market

For

per

sona

l use

onl

y

nUView Gels – The Market

• US$150 million pa Global market:

� US (45%), Europe (40%), Other (15%)

• 60% of the market use pre-made gels

• NuSep has <1% market share

• Two Competitors own 95% of the US Gels Market:

� Invitrogen

� Bio-Rad

• NuSep’s Gels now compatible with both Invitrogen & Bio-Rad tanks

Bio-Rad50%

Invitrogen45%

Other5%

6,000,000 Bio-Rad & Invitrogen Gels SoldIn the US Every Year

nUView Gels are ‘Best in Class’

For

per

sona

l use

onl

y

ProteoIQ – The Market

• US$130m pa global market and relatively untapped (10,000 labs) –US (50%) & Europe (25%)

• Data analysis is major bottle-neck restricting proteomics research

• Users spend weeks analysing data

• ProteoIQ software processes this data in hours

• US sales accelerating post:

• Release of Version 2.2

• Annual License

Market in early growth phase

Intro Growth Maturity Decline

Product Lifecycle

For

per

sona

l use

onl

y

ProteoIQ - Best in Class

ProteoIQ - $12,600 (V2.2)Label FreeSILACiTRAQ/TMT

Non-Linear DynamicsProgenisis - $28,000Label Free Quant

AB Sciex – Protein Pilot$30,000 ($10,000 annual)iTRAQ/TMTOnly AB instruments

Proteome Software - Scaffold$8,000 ($2,000 annual)iTRAQ/TMT, Spectral Counting

MaxQuantFreeSILAC

ProteoIQ - the ‘Google’ for proteins

For

per

sona

l use

onl

y

Consumables Summary

• Gels & IQ are ‘Best in Class’

• Distribution is the key to sales growth

� Signed $850k Distribution Agreement with Thermo

� Signed 3 new Asian Distributors

• A Cash Cow to fund the Other Divisions

For

per

sona

l use

onl

y

SpermSep

• IVF SpermSep Market $110m worldwide

• $5m Australian IVF SpermSep market

For

per

sona

l use

onl

y

SpermSep Summary

• A Product Developed by Clinicians

• Successful Clinical Trial in 2008 with 3 live births from 9 women

• New Cartridge Patent lodged

• $1m to Fund Final Clinical trial from 15¢ Options in March 2012

• Market Launch Late 2012

• Australian Market $5m pa

• No Commercial Competition

• Applications in the veterinary fieldFor

per

sona

l use

onl

y

NuSep Plasma Fractionation

2010Blue Sky

2011Now Reality

For

per

sona

l use

onl

y

• $US10 billion market worldwide, Dominated by 5 fractionators

• NuSep is focused on the $US1billion Niche Asian market

• Most Asian Countries ‘Waste’ over 50% of their plasma

• NuSep can process this ‘Currently Unprocessable Plasma’ This:

� Saves $10m - $100m per Country per year

� Enables these countries to become self sufficient

NuSep is focused on a niche market -

Asian countries that want to process

their Currently Unprocessable Plasma.

The Blood Plasma Market

For

per

sona

l use

onl

y

Plasma - the Liquid Gold

US$100 Barrel US $120 LitreFor

per

sona

l use

onl

y

The Numbers

• Australia Spends ~$400m pa on Plasma Products with a Population of 22m

• Singapore has a population of 5m

• Malaysia has a populationof 25m

• Thailand has a populationof 65m

• Philippines has a population of 90m

Supplier Products Purchased

2008-09

($M)

2009-10

($M)

CSL Ltd Plasma products

• albumin products

• immunoglobulin products (including IVIg and hyperimmune products)

• plasma-derived clotting factors

Diagnostic reagent products

• blood grouping sera

• reagent red cell products

Imported Blood Products

• Factors XI and XIII

• IVIg standing offer

162.09 186.16

Baxter Healthcare Pty Ltd

Imported Blood Products

• Recombinant Factor VIII

• Protein C

• Factor VII concentrate

• Factor Eight inhibitor Bypass Agent (FEIBA)

• WinRho

84.09 90.62

Wyeth Australia Pty Ltd

Imported Blood Products

• Recombinant Factor VIII

• Recombinant Factor IX

48.65 48.94

Novo Nordisk Pharmaceuticals Pty Ltd

Imported Blood Products

• Recombinant Factor VIIIa

17.40 26.42

Octapharma Pty Ltd

Imported Blood Products

• IVIg Standing Offer

46.90 48.69

TOTAL 359.13 400.83

Source: National Blood Authority Australia Annual Report 2009-10

For

per

sona

l use

onl

y

PrIME - the Key toThe Liquid Gold

Current Technology PrIME Technology

•Double the final product yield•Process small volumes•Disposable production process

•Produce new products•Increase product safety•Reduce process time

• Process Currently Unprocessable Plasma

For

per

sona

l use

onl

y

Mini Mill Business ModelStarts in Singapore

For

per

sona

l use

onl

y

Steps to Success

� Unique Selling Proposition• Ability to process small volumes• Ability to process ‘Currently Unprocessable Plasma’

� Government Support• Singapore EDB Financial Funding • Agreed to Clinical trial in Singapore

� Pharmaceutical Industry Support • LOI from Philippine based United Laboratories

For

per

sona

l use

onl

y

PrIME Timeline

Manufacture initial

production batches of

IVIG and Albumin.

(12 months)

Gain HSA approval for NuSep Asia’s manufacturing facility. (12 months)

Complete clinical trials of the

IVIG and Albumin in

Singapore.

(24 months)

First sales of IVIG and Albumin in Singapore.(24 months)

Pursue expansion into additional Asian markets

-Thailand- Indonesia- China- India - Malaysia- Philippines

Build out ofManufacturing facility(9 -12 months)

FEED* report

Site selection

*Front End Engineering Design

LOI Philippines

EDB Funding & SupportF

or p

erso

nal u

se o

nly

PrIME Singapore Budget

2011

S$M

2012

S$M

2013

S$M

2014

S$M

2015

S$M

2016

S$M

2017

S$M

Sales - - $4.75 $11.5 $24.5 $32.7 $36

Gross Profit

($0.5) ($0.3) $3.3 $8.3 $17.6 $23.9 $26.4

EBITDA ($2.7) ($2.8) $1.0 $5.5 $14.8 $21 $23.5

NPAT ($2.8) ($3) $0.5 $4.9 $11.8 $16.9 $19

Budget is in Singapore dollars. 1 S$ = A$.76For

per

sona

l use

onl

y

Recent Achievements

• Select the Singapore Tech View Facility

• Employ Director GMP Operations & Director

Regulatory Affairs

• Sign Plasma Supply Agreement

• Receive Singapore Government Funding & Support

• LOI from Philippine based United Laboratories

• Discussions with other Asian CountriesFor

per

sona

l use

onl

y

Conclusion

• Consumables Business (Gels/IQ) is Profitable

• $1m investment required to complete the SpermSep Locked in via March 2012 Share Options

• The PrIME Mini Mill is Game Changing

• Singapore validates the PrIME Mini Mill and now has Singapore Government & Industry Support

For

per

sona

l use

onl

y

For

per

sona

l use

onl

y